ALNY FY 2018 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M-16.7% YoY

Gross Profit

$73M97.6% margin

Operating Income

-$815M-1087.6% margin

Net Income

-$761M-1016.6% margin

EPS (Diluted)

$-7.57

Cash Flow

Operating Cash Flow

-$563M

Free Cash Flow

-$690M

Stock-Based Comp.

$158M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$273M

Stockholders' Equity

$1.3B

Cash & Equivalents

$420M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$90M	-16.7%
Gross Profit	$73M	$77M	-4.5%
Operating Income	-$815M	-$500M	-62.9%
Net Income	-$761M	-$491M	-55.1%